Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In Ashkenazi patients, ERCC2 and MTHFR genes' SNPs were associated with age at diagnosis (ERCC2: p=0.025, MTHFR: p=0.0005); a P53 polymorphism, APOE and Rb SNPs with a family history of cancer (P53 p=0.034;APOE p=0.04, Rb p= 0.022); DCC SNP with tumor location (p=0.014); and p15 SNP with tumor grade (p=0.032).
|
15523694 |
2005 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Another way of inactivation of this CDKI is by hypermethylation of 5'CpG islands in the promoter region of the p15INK4B gene and this inactivation seems to be a frequent event in various haematological malignancies.
|
15737564 |
2005 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Promoter hypermethylation of p15(INK4b) was more common in ovarian cancer (30.8% for the 52 cases) than in normal ovaries (5% for the 40 controls without ovarian cancer; P = 0.005) but not methylation of p16INK4a (25% for cancer versus 37.5% for normal; P = 0.288).
|
16000597 |
2005 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
P16 (INK4A) and p15 (INK4B) are thought to act as tumor suppressors, since their inactivation and/or deletion are observable in various types of malignancies.
|
15590562 |
2004 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The p14(ARF), p15(INK4B), and p16(INK4A) genes are important negative cell-cycle regulators often inactivated by deletions, mutations, or hypermethylation in malignancy.
|
12970781 |
2003 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Epigenetic silencing of the p16 and p15 genes by promoter methylation are commonly observed in human epithelial malignancies, including head and neck squamous cell carcinomas (HNSCC).
|
12932666 |
2003 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
By examining the methylation patterns of these genes, 3 differential methylation patterns were recognized: hypermethylation was more frequent in cancer than in IM (DAP-kinase, p14, p15 and p16); comparable frequencies of methylation in cancer and IM (E-cadherin and hMLH1); and no methylation (GSTP1).
|
12448005 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Alterations in G(1)/S phase regulating proteins like the retinoblastoma protein, cyclins D and E, cdk4 and 6, cdk inhibitors p16(INK4A) and p15(INK4B), and p53 are among the most frequent aberrations observed in human malignancies.
|
11986936 |
2002 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The genes encoding the cyclin-dependent kinase inhibitors p16INK4A and p15INK4B are potent TSGs, and correlations between their inactivation and disease progression have also been reported in various malignancies.
|
11243384 |
2001 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The INK4A and INK4B loci are located at 9p21 and have been implicated in the tumorigenesis of various human malignancies.
|
11369056 |
2001 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We have now analyzed a series of promoter hypermethylation changes in 12 genes (p16(INK4a), p15(INK4b), p14(ARF), p73, APC,(5) BRCA1, hMLH1, GSTP1, MGMT, CDH1, TIMP3, and DAPK), each rigorously characterized for association with abnormal gene silencing in cancer, in DNA from over 600 primary tumor samples representing 15 major tumor types.
|
11309270 |
2001 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of the cyclin-dependent kinase inhibitor p15(INK4B) frequently is altered in myeloid malignancies.
|
10812241 |
2000 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cyclin-dependent kinase (CDK) inhibitors represented by the INK4 family (including p16(INK4a, CDKN2A), p15(INK4b, CDKN2B), p18(INK4c, CDKN2C), and p19(INK4d, CDKN2D)) are regulators of the cell cycle shown to be aberrant in many types of human cancer.
|
10918395 |
2000 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Alterations of p16 and p15 genes have been reported in cancer cell lines and in certain malignant neoplasm.
|
10958872 |
2000 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
On the other hand, hereditary mutations of TP57KIP2, P15INK4B, and P16INK4A, which affect the cell cycle similar to TP53, were observed in some types of cancer.
|
10484981 |
1999 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The reversibility of this epigenetic inactivation of the p16 and p15 genes in MM may also provide a broad clinical application in the development of new therapeutic interventions in this uniformly fatal form of cancer.
|
10492069 |
1999 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Alterations of the INK4A and INK4B genes occur frequently in certain primary malignant neoplasms.
|
9890173 |
1999 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, p16 and p15 have been identified as commonly inactivated tumour suppressor genes in haematological malignancies.
|
9792305 |
1998 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Messenger RNA (mRNA) analysis showed that CDKN2C is expressed in all hepatoblastoma samples studied, while both CDKN2A and CDKN2B genes are not transcribed in the cancer specimens as well as in the matched normal liver tissues.
|
9537438 |
1998 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, a significant up-regulation of p15INK4B gene expression is observable during the development of the acute phase of malignancy.
|
9825572 |
1998 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The fact that the p16/INK4a and p15/INK4b genes are frequently inactivated in human malignancies and that p16/INK4a null mice spontaneously develop B-cell lymphomas prompted us to examine the status of both genes in Burkitt's Lymphoma (BL).
|
9473234 |
1998 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
p18INK4C, a cyclin-dependent kinase inhibitor, is a homologue of p15INK4B and p16INK4A which are frequently altered in a variety of malignancies.
|
9401081 |
1997 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The results indicate that homozygous deletions of p16INK4 and/or p15INK4B genes may play a role in a subset of primary gynecologic malignancy.
|
9159345 |
1997 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The cell cycle regulators p16INK4 and p15INK4B have been mapped to the minimal region of overlap for chromosome 9p21 deletions, observed in a number of malignancies, suggesting that they could be tumor suppressor genes (TSGs).
|
8641406 |
1996 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Structural genetic changes of tumor suppressor genes MTS-1/INK4A and MTS-2/INK4B were demonstrated in a variety of human cancers but not in thyroid cancer until now.
|
8957499 |
1996 |